LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/Continuous Expansion Spacer System Cleared by FDA
Spine

Continuous Expansion Spacer System Cleared by FDA

February 9, 2018 2 min read Premium comments

Advertisement

Continuous Expansion Spacer System Cleared by FDA
FORZA XP Expandable Spacer System / Courtesy of Orthofix International N.V.
#orthofix#backpainSecondary#degenerativediscdisease#fdaclearance#expandablespacer

The FDA has given 510(k) clearance for an expandable spacer system made by Orthofix International N.V.

The clearance of the FORZA XP Expandable Spacer System was announced by the company on February 6, 2018. At the same time, the company announced the limited market launch of the system for the U.S.

The company said the FORZA was unlike other incremental expandable interbody devices, in that their systems allows for a “continuous controlled expansion and a custom fit to the disc space. Once the desired expansion is achieved the device features automatic locking which further adds to its ease of use.”

After insertion into the disc space to fit a patient’s anatomy, the spacer, like other systems, is designed to restore normal disc height in patients suffering from degenerative disc disease.

The FORZA is made primarily of titanium alloy and used for PLIF (Posterior Lumbar Interbody Fusion) and TLIF (Transforaminal Lumbar Interbody Fusion) procedures.

Orthofix Spine Fixation President Ray Fujikawa said the systems, “offers an industry-leading 6.5mm starting height and also enables surgeons to place bone graft material inside the device after implantation. The ability to pack our new expandable device with bone graft post expansion is extremely important to ensure proper contact of the material with the vertebral endplates.”

Indications

According to an FDA summary, the system is indicated for “spinal fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one or two contiguous levels in the lumbar spine (L2-S1). DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies. DDD patients may also have up to Grade 1 spondylolisthesis at the involved levels. These patients may have had a previous non-fusion surgery at the involved level(s).”

Advertisement

“In addition, the system is intended for use with autograft and/or allograft comprised of cancellous and/or corticocancellous bone graft and supplemental fixation” (i.e., Firebird Spinal Fixation System).

Patients must have undergone a regimen of at least six months of non-operative treatment prior to being treated with FORZA XP Expandable Spacer System.

The clearance request was submitted on September 7, 2017 and clearance was granted on January 19, 2018.

Predicate Devices

Predicate devices included the Atlas Spine Expandable Interbody System, the FORZA Spacer System, the Centurion POCT (Posterior Occipital Cervico-Thoracic) System, the SKYHAWK Interbody Fusion System and the SKYHAWK Lateral Plate System.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy